<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00871429</url>
  </required_header>
  <id_info>
    <org_study_id>MEL080108</org_study_id>
    <nct_id>NCT00871429</nct_id>
  </id_info>
  <brief_title>Skin Care for Cancer Patients: A Product Satisfaction Survey</brief_title>
  <official_title>Selected Skin Products for Cancer Patients: A Product Satisfaction Survey</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done because the investigators would like to evaluate product
      satisfaction of three test products (product A, product B, product C) that are available at
      any drug store. This will be done by measuring any changes in the subjects' answers to the
      Skindex-16 questionnaire at two time points (at screening and baseline visit and at follow-up
      visit) and by evaluating their responses to the product satisfaction survey that will be
      given to them by a study coordinator.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to evaluate product satisfaction of the following test
      articles A, B, and C: Lindi Skin soothing balm (product A), Lindi Skin face serum (product
      B), and Lindi Skin face wash (product C). This will be done by measuring change in Skindex-16
      questionnaire at two time points (baseline and follow-up visits) and by evaluating responses
      to the investigator administered product satisfaction survey.

      The secondary objective of this study is to see if there is any correlation between product
      satisfaction and grade of skin toxicity based on NCI-CTCAE v.3.0 scale.

      Participants in this study will be patients seen at the Northwestern University SERIES clinic
      or Lurie Cancer Center who are receiving chemotherapeutic and or radiation treatments.
      Subjects who choose to participate complete a Skindex16 questionnaire, and will after
      consenting to participate, be given all three test articles A, B, and C to use daily for one
      month. (These test articles are currently marketed products classified by the FDA as
      cosmetics).

      At the return visit, 1 month after baseline visit, the participant will be asked to return
      the test articles and complete an investigator administered product satisfaction
      questionnaire for each test article used. 100 participants will be surveyed. Subjects will be
      telephoned to check for product compliance after 1 week and 2 week intervals.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Product Satisfaction of the Following Test Articles A, B, and C: Lindi Skin Soothing Balm (Product A), Lindi Skin Face Serum (Product B), and Lindi Skin Face Wash (Product C)</measure>
    <time_frame>one month of use</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Skin Toxicity Grades 0 to 5 Using The NCI Common Terminology Criteria for Adverse Events (CTCAE) v 3.0 at Baseline Visit and 1 Month Follow-up After Using Lindi Products.</measure>
    <time_frame>one month</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">99</enrollment>
  <condition>Skin Toxicity</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Lindi skin care products</intervention_name>
    <description>Subjects will then be instructed to apply all three products daily for 1 month.
The products include: Lindi Skin soothing balm (product A), Lindi Skin face serum (product B, and Lindi Skin face wash (product C).</description>
    <other_name>Lindi Skin soothing balm (product A)</other_name>
    <other_name>Lindi Skin face serum (product B)</other_name>
    <other_name>Lindi Skin face wash (product C)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who are at least 18 years of age.

          -  Subjects who have the willingness and ability to understand and provide informed
             consent to participate in the study and are able to communicate with the investigator.

          -  Subjects who are seen in the SERIES clinic or Lurie Cancer Center and who are
             receiving chemotherapy and/or radiation treatment for malignancy

          -  Subjects who have grade &lt;2 skin toxicity based on NCI-CTCAE v3.0 scale.

          -  Subjects who are routine cosmetics users

        Exclusion Criteria:

          -  Under 18 years of age.

          -  Known allergy to any of the ingredients in the assigned products (Appendix C).

          -  Subjects who have grade 2,3,4 skin toxicity based on NCI-CTCAE v3.0 scale.

          -  Subjects who are pregnant, breast feeding, or those who are planning on becoming
             pregnant during test period.

          -  Subjects who use multiple topical agents on study areas
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mario E Lacouture, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University Department of Dermatology</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Haley AC, Calahan C, Gandhi M, West DP, Rademaker A, Lacouture ME. Skin care management in cancer patients: an evaluation of quality of life and tolerability. Support Care Cancer. 2011 Apr;19(4):545-54. doi: 10.1007/s00520-010-0851-8. Epub 2010 Mar 25.</citation>
    <PMID>20336328</PMID>
  </reference>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2009</study_first_submitted>
  <study_first_submitted_qc>March 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2009</study_first_posted>
  <results_first_submitted>May 5, 2010</results_first_submitted>
  <results_first_submitted_qc>July 14, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 10, 2010</results_first_posted>
  <last_update_submitted>February 24, 2015</last_update_submitted>
  <last_update_submitted_qc>February 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2015</last_update_posted>
  <responsible_party>
    <name_title>Mario Lacouture MD</name_title>
    <organization>Northwestern University</organization>
  </responsible_party>
  <keyword>skin toxicity</keyword>
  <keyword>cancer patients</keyword>
  <keyword>adverse effects</keyword>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants in this study will be patients seen at the Northwestern University SERIES clinic or Lurie Cancer Center who are receiving chemotherapeutic and or radiation treatments.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Lindi Skin Participant Flow</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="99"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Questionnaire not completed</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cancer Patients Using Lindi Skin Products</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="99"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Product Satisfaction of the Following Test Articles A, B, and C: Lindi Skin Soothing Balm (Product A), Lindi Skin Face Serum (Product B), and Lindi Skin Face Wash (Product C)</title>
        <time_frame>one month of use</time_frame>
        <population>the number of participants for analysis was determined per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Lindi Skin Soothing Balm (Product A)</title>
          </group>
          <group group_id="O2">
            <title>Lindi Skin Face Wash (Product C)</title>
          </group>
          <group group_id="O3">
            <title>Lindi Skin Face Serum (Product B)</title>
          </group>
        </group_list>
        <measure>
          <title>Product Satisfaction of the Following Test Articles A, B, and C: Lindi Skin Soothing Balm (Product A), Lindi Skin Face Serum (Product B), and Lindi Skin Face Wash (Product C)</title>
          <population>the number of participants for analysis was determined per protocol.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participant Product Satisfaction: Very Good/Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.67"/>
                    <measurement group_id="O2" value="73.68"/>
                    <measurement group_id="O3" value="88.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participant Product Satisfaction: OK</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.00"/>
                    <measurement group_id="O2" value="23.68"/>
                    <measurement group_id="O3" value="9.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participant Product Satisfaction: Bad/Very Bad</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.33"/>
                    <measurement group_id="O2" value="2.63"/>
                    <measurement group_id="O3" value="2.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Skin Toxicity Grades 0 to 5 Using The NCI Common Terminology Criteria for Adverse Events (CTCAE) v 3.0 at Baseline Visit and 1 Month Follow-up After Using Lindi Products.</title>
        <time_frame>one month</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Serious and non-serious adverse events were not collected/assessed.</desc>
      <group_list>
        <group group_id="E1">
          <title>Lindi Skin Soothing Balm (Product A)</title>
        </group>
        <group group_id="E2">
          <title>Lindi Skin Face Wash (Product C)</title>
        </group>
        <group group_id="E3">
          <title>Lindi Skin Face Serum (Product B)</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>No limitations of the trial identified.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Mandy Browning</name_or_title>
      <organization>Northwestern University</organization>
      <phone>312-695-6829</phone>
      <email>mandybrowning2015@u.northwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

